% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • godwinpeak godwinpeak Apr 18, 2013 3:31 PM Flag

    No one is going to buy Affymax. Only asset it has is "blue sky" Takeda deal.

    No entity will buy the Affymax company and pay shareholders. To do so would bring along all of the headaches, time, energy and expense of the products liability and securities litigation. The ONLY ASSET it has that anybody may be interested in buying would be the "blue sky" Takeda royalties/milestone deal for the recalled and disgraced Omontys drug. But Omontys itself is beset with problems: No unmet medical need; cannot be approved for CKD patients generally; industry standard Epogen/Arnasep with proven safety profiles; biosimilars soon to be on the market; and a disgraced reputation, among others. I predict a bankrupt Affymax will sell the Takeda deal in its Chapter 11 reorganization and set aside sales proceeds for the litigation claims.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.076+0.0010(+1.33%)Jun 24 2:10 PMEDT